{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:53:55Z","timestamp":1760234035936,"version":"build-2065373602"},"reference-count":60,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Nucles(t)ide analogs (NAs) are effective for chronic hepatitis B (CHB). NAs suppress hepatic decompensation and hepatocarcinogenesis, leading to a dramatic improvement of the natural course of patients with CHB. However, renal dysfunction is becoming an important issue for the management of CHB. Renal dysfunction develops in patients with the long-term treatment of NAs including adefovir dipivoxil and tenofovir disoproxil fumarate. Recently, several studies have reported that the newly approved tenofovir alafenamide (TAF) has a safe profile for the kidney due to greater plasma stability. In this mini-review, we discuss the effectiveness of switching to TAF for NAs-related renal tubular dysfunction in patients with CHB.<\/jats:p>","DOI":"10.3390\/life11030263","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T14:08:16Z","timestamp":1616508496000},"page":"263","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-3149","authenticated-orcid":false,"given":"Tomoya","family":"Sano","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7064-4325","authenticated-orcid":false,"given":"Takumi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Ide","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Amano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiichiro","family":"Kuwahara","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruko","family":"Arinaga-Hino","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Torimura","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Trepo","year":"2014","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrgastro.2011.33","article-title":"Hepatitis B therapy","volume":"8","author":"Kwon","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/17474124.2014.909724","article-title":"Current developments in nucleoside\/nucleotide analogues for hepatitis B","volume":"8","author":"Lo","year":"2014","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"Hosaka","year":"2013","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1517\/14740338.2016.1139573","article-title":"DNA polymerase inhibitors for treating hepatitis B: A safety evaluation","volume":"15","author":"Mak","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.27894","article-title":"Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects","volume":"62","author":"Wong","year":"2015","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00535-013-0779-0","article-title":"Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B","volume":"49","author":"Tanaka","year":"2014","journal-title":"J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Atef, M., Zayed, N., Salama, R., Abdel Alem, S., Yousof, H., Saber, M., Hamed, M., and Yosry, A. (2020). Is urinary beta2-microglobulin a reliable marker for assessment of renal tubular dysfunction in chronic hepatitis B patients receiving tenofovir therapy?. Eur. J. Gastroenterol. Hepatol.","DOI":"10.1097\/MEG.0000000000001977"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.23044","article-title":"Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil","volume":"50","author":"Ha","year":"2009","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5009\/gnl.2010.4.3.389","article-title":"Fanconi\u2019s Syndrome Associated with Prolonged Adefovir Dipivoxil Therapy in a Hepatitis B Virus Patient","volume":"4","author":"Jung","year":"2010","journal-title":"Gut Liver"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcv.2014.09.016","article-title":"Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal","volume":"61","author":"Vigano","year":"2014","journal-title":"J. Clin. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jhep.2011.03.030","article-title":"Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B","volume":"55","author":"Mauss","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/00365548.2013.840921","article-title":"Recurrent bone fractures due to tenofovir-induced renal phosphate wasting","volume":"46","author":"Koenig","year":"2014","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/107906320101300303","article-title":"Examining the substance use patterns and treatment needs of incarcerated sex offenders","volume":"13","author":"Peugh","year":"2001","journal-title":"Sex. Abus."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2006.04.047","article-title":"Tubular transporters and clearance of adefovir","volume":"540","author":"Servais","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/mol.106.028233","article-title":"Functional involvement of multidrug resistance-associated protein 4 (MRP4\/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir","volume":"71","author":"Imaoka","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/cis772","article-title":"Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: A pharmacogenetic study","volume":"55","author":"Nishijima","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1053\/ajkd.2003.50037","article-title":"Drug-induced Fanconi\u2019s syndrome","volume":"41","author":"Izzedine","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/14656566.2012.649727","article-title":"Adefovir dipivoxil in chronic hepatitis B: History and current uses","volume":"13","author":"Segovia","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2147\/DDDT.S192632","article-title":"Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible?","volume":"13","author":"Qian","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jcpt.12050","article-title":"Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low-dose adefovir dipivoxil: A case report and literature review suggesting ethnic predisposition","volume":"38","author":"Wu","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/apt.13659","article-title":"Review article: Long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients","volume":"44","author":"Lampertico","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e01064-18","DOI":"10.1128\/AAC.01064-18","article-title":"No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection","volume":"62","author":"Cathcart","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13643-019-1126-1","article-title":"Antiviral treatment for treatment-naive chronic hepatitis B: Systematic review and network meta-analysis of randomized controlled trials","volume":"8","author":"Wong","year":"2019","journal-title":"Syst. Rev."},{"key":"ref_31","first-page":"2049936120985954","article-title":"Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B","volume":"8","author":"Roade","year":"2021","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: A randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"Mills","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/apt.14945","article-title":"Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment","volume":"48","author":"Wong","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/jmv.25515","article-title":"Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B","volume":"91","author":"Hagiwara","year":"2019","journal-title":"J. Med. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/jmv.25644","article-title":"Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate","volume":"92","author":"Uchida","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Rashidi-Alavijeh, J., Straub, K., Achterfeld, A., Wedemeyer, H., Willuweit, K., and Herzer, K. (2020). Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience. Transpl. Infect. Dis., e13522.","DOI":"10.1111\/tid.13522"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e13740","DOI":"10.1111\/ctr.13740","article-title":"Long-term outcomes with oral therapy in liver transplant recipients with hepatitis B","volume":"33","author":"Saab","year":"2019","journal-title":"Clin. Transpl."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zeng, Q.L., Yu, Z.J., Ji, F., Li, G.M., Zhang, G.F., Xu, J.H., Chen, Z.M., Cui, G.L., Li, W., and Zhang, D.W. (2021). Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. Clin. Infect. Dis.","DOI":"10.1093\/cid\/ciaa1939"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jmv.25692","article-title":"Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B","volume":"92","author":"Tamaki","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_42","first-page":"A78","article-title":"Cost-effectiveness analysis of first-line administration of tenofovir alafenamide (TAF), a novel nucleotide reverse transcrip-tase inhibitor (NRTI), for the management of chronic hepatitis b (CHB) in the united states (US)","volume":"20","author":"Dusheiko","year":"2017","journal-title":"Value Health"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00535-020-01680-0","article-title":"Adverse events of nucleos(t)ide analogues for chronic hepatitis B: A systematic review","volume":"55","author":"Mendes","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/QAD.0000000000002496","article-title":"The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen","volume":"34","author":"Taramasso","year":"2020","journal-title":"AIDS"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"ofz414","DOI":"10.1093\/ofid\/ofz414","article-title":"Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide","volume":"6","author":"Schafer","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s15010-018-1227-0","article-title":"A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015\u20132017","volume":"47","author":"Gomez","year":"2019","journal-title":"Infection"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Lomiak, M., Stepnicki, J., Mikula, T., and Wiercinska-Drapalo, A. (2021). Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group. Int. J. STD AIDS, 956462420983699.","DOI":"10.1177\/0956462420983699"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jgh3.12481","article-title":"Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients","volume":"5","author":"Lee","year":"2021","journal-title":"JGH Open"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: A randomised, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"Lampertico","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/liv.14482","article-title":"Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B","volume":"40","author":"Ogawa","year":"2020","journal-title":"Liver Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/jvh.13053","article-title":"Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide","volume":"26","author":"Fong","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1111\/jgh.14686","article-title":"Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate","volume":"34","author":"Kaneko","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_53","first-page":"12","article-title":"Short-term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alaferamide for chronic hepatitis B","volume":"14","author":"Sano","year":"2021","journal-title":"Biomed. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ki.2011.124","article-title":"Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy","volume":"80","author":"Dauchy","year":"2011","journal-title":"Kidney Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13098-020-0517-8","article-title":"Analysis of risk factors for carotid intima-media thickness in patients with type 2 diabetes mellitus in Western China assessed by logistic regression combined with a decision tree model","volume":"12","author":"Zhou","year":"2020","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/00365517209081057","article-title":"The serum levels and urinary excretion of 2 -microglobulin in apparently healthy subjects","volume":"29","author":"Evrin","year":"1972","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1681\/ASN.2015121308","article-title":"Renal Aging: Causes and Consequences","volume":"28","author":"Hughes","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_58","first-page":"525","article-title":"Tenofovir alafenamide revisited","volume":"28","year":"2020","journal-title":"Infez. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.cgh.2018.08.037","article-title":"Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir","volume":"17","author":"Trinh","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.dld.2020.06.037","article-title":"Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide","volume":"52","author":"Roade","year":"2020","journal-title":"Dig. Liver Dis."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/3\/263\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:39:31Z","timestamp":1760161171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/3\/263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["life11030263"],"URL":"https:\/\/doi.org\/10.3390\/life11030263","relation":{},"ISSN":["2075-1729"],"issn-type":[{"type":"electronic","value":"2075-1729"}],"subject":[],"published":{"date-parts":[[2021,3,23]]}}}